Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss.
BACKGROUND
Recently, vaspin was identified as a novel adipokine with insulin-sensitizing effects that might be implicated in endogenous glucose regulation. Our objective was to evaluate the impact of acute weight loss and metabolic changes on serum vaspin concentrations in morbidly obese subjects following laparoscopic Roux-en-Y gastric bypass (RYGB) surgery.


METHODS
Longitudinal, clinical intervention study in 33 morbidly obese subjects before and 12 months after RYGB was conducted. Fasting serum concentrations of vaspin were measured by a commercially available ELISA and correlated with BMI, parameters of insulin sensitivity, and other biochemical measurements. Fasting insulin sensitivity was estimated using the homeostasis model assessment (HOMA) of insulin resistance.


RESULTS
RYGB-induced weight loss resulted in a reduction of circulating vaspin, leptin, insulin, and C-peptide levels as well as of BMI, HbA1c, and HOMA (p < 0.0001, respectively). Changes in serum vaspin concentrations correlated positively with those in HOMA, insulin, C-peptide, HbA1c, and leptin (p < 0.05, respectively) levels. The association between percent change of vaspin and HOMA remained significant even after the adjustment for RYGB-induced changes in BMI.


CONCLUSIONS
Following RYGB surgery, changes in serum vaspin concentrations correlate significantly with the reduction of circulating leptin, insulin, and C-peptide levels and with the amelioration of insulin sensitivity. However, further studies have to elucidate whether vaspin is only a biomarker for body-weight-related changes of insulin sensitivity or whether it is implicated in the regulation of human glucose homeostasis.
Handisurya
Ammon
A
Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Riedl
Michaela
M
Vila
Greisa
G
Maier
Christina
C
Clodi
Martin
M
Prikoszovich
Thomas
T
Ludvik
Bernhard
B
Prager
Gerhard
G
Luger
Anton
A
Kautzky-Willer
Alexandra
A
D000328:Adult; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood; D005260:Female; D015390:Gastric Bypass; D006706:Homeostasis; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance / Q000502:physiology; D020738:Leptin / Q000097:blood; D008297:Male; D008593:Menopause / Q000097:blood; D009767:Obesity, Morbid / Q000097:blood* / Q000378:metabolism / Q000601:surgery; D015843:Serpins / Q000097:blood*; D015431:Weight Loss / Q000502:physiology*
D015415:Biomarkers; D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D020738:Leptin; C507339:SERPINA12 protein, human; D015843:Serpins